IN BRIEF: Arix Bioscience ends buyback; portfolio interest pursues IPO

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Ends share buyback ...

Alliance News 20 October, 2021 | 2:15PM
Email Form Facebook Twitter LinkedIn RSS

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Ends share buyback programme to pursue its "promising" pipeline of biotech investments. Says it spend GBP11.5 million in the buyback, which began in March. The company repurchased 6.4 million shares for GBP1.79 each, amounting to around 4.7% of share capital.

Portfolio company focused on developing melanoma, Aura Biosciences Inc, pursues initial public offering on the Nasdaq Stock Market. Another portfolio company, LogicBio Therapeutics Inc, undertakes Phase 1/2 Sunrise clinical trial of in-vivo genome editing in children. The trial will evaluate the safety, tolerability and efficacy of its LB-001 genome therapy, the company says. LogicBio is on track to present interim data from its trials by the end of 2021, it adds.

Says David Cristina joins Arix as a secondee from Fosun International, where Cristina was Head of Fosun's European Healthcare Investment Team.

Current stock price: 140.00 pence, up 0.4% on Wednesday

Year-to-date change: down 36%

By Scarlett Butler; scarlettbutler@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Arix Bioscience PLC 128.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.